Financhill
Sell
17

MNPR Quote, Financials, Valuation and Earnings

Last price:
$29.48
Seasonality move :
-9.44%
Day range:
$28.24 - $34.86
52-week range:
$1.72 - $54.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.33x
Volume:
42.4K
Avg. volume:
35.7K
1-year change:
839.85%
Market cap:
$183.4M
Revenue:
--
EPS (TTM):
-$1.99

Earnings Data

Next earnings date for MNPR
May 09
2025
Most recent earnings per share
-$2.75
Missed by $2.33
(Mar 28/2025)
Consensus Estimate
-$0.42
(Mar 28/2025)

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

MNPR Quarterly Earnings History

Date Quarter Revenue Forecast Actual Revenue Reported EPS Consensus EPS Beat/Miss
06/30/2025 Q2 -- -- -- -$0.62 --
05/09/2025 Q1 -- -- -- -$0.57 --
03/28/2025 Q4 -- -- -$2.75 -$0.42 -$2.33
11/08/2024 Q3 -- -- -$0.37 -$1.17 $0.80
08/09/2024 Q2 -- -- -$0.50 -$0.47 -$0.03
05/09/2024 Q1 -- -- -$0.50 -$0.85 $0.35
03/28/2024 Q4 -- -- -$0.62 -$0.85 $0.23
11/09/2023 Q3 -- -- -$0.69 -$0.95 $0.26
08/11/2023 Q2 -- -- -$0.80 -$0.95 $0.15
05/11/2023 Q1 -- -- -$0.95 -$1.08 $0.13
03/23/2023 Q4 -- -- -$1.15 -$1.03 -$0.13
11/10/2022 Q3 -- -- -$0.95 -$1.08 $0.13
08/11/2022 Q2 -- -- -$1.10 -- --
05/12/2022 Q1 -- -- -$0.95 -- --
03/24/2022 Q4 -- -- -$1.05 -- --
11/12/2021 Q3 -- -- -$1.00 -- --
08/12/2021 Q2 -- -- -$0.85 -- --
05/13/2021 Q1 -- -- -$0.80 -- --
03/25/2021 Q4 -- -- -$0.95 -- --
11/12/2020 Q3 -- -- -$0.75 -- --
08/06/2020 Q2 -- -- -$0.70 -- --
05/07/2020 Q1 -- -- -$0.50 -- --
03/27/2020 Q4 -- -- -$0.57 -- --
09/30/2019 Q3 -- -- -$0.35 -- --
06/30/2019 Q2 -- -- -$0.43 -- --
03/31/2019 Q1 -- -- -$0.66 -- --
12/31/2018 Q4 -- -- -$0.43 -- --
09/30/2018 Q3 -- -- -$0.31 -- --
06/30/2018 Q2 -- -- -$0.36 -- --
03/31/2018 Q1 -- -- -$0.42 -- --
12/31/2017 Q4 -- -- -$0.34 -- --
09/30/2017 Q3 -- -- -$7.14 -- --
06/30/2017 Q2 -- -- -$0.28 -- --
03/31/2017 Q1 -- -- -$0.18 -- --

Monopar Therapeutics Earnings Questions

  • How Much did Monopar Therapeutics Generate in Revenue Last Quarter?

    Monopar Therapeutics reported -- worth of top line sales in its most recent quarter.

  • Did Monopar Therapeutics Beat Earnings Last Quarter?

    Monopar Therapeutics announced earnings per share of -$2.75 which represents a miss of analyst forecast a -$0.42 per share.

  • Is Monopar Therapeutics Profitable?

    Monopar Therapeutics reported -- that represents -- per share over the last quarter.

  • What is the Analyst Consensus for Monopar Therapeutics EPS Next Year?

    Monopar Therapeutics's earnings are forecast to decrease from -$4.11 per share to -$1.77 per share next year representing a decrease of -35.93%.

  • When is Monopar Therapeutics's Earnings Date?

    Monopar Therapeutics's next earnings date is May 9, 2025.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Okta a Good Stock to Buy?
Is Okta a Good Stock to Buy?

Okta (NASDAQ:OKTA) is used by some of the largest firms…

Is Fidelity High Dividend ETF a Good Investment Now?
Is Fidelity High Dividend ETF a Good Investment Now?

Fidelity’s High Dividend ETF (FDVV) is a fund that offers…

Is Kinder Morgan Dividend Yield Worth It?
Is Kinder Morgan Dividend Yield Worth It?

Kinder Morgan (NYSE:KMI) is a major energy infrastructure company in…

Stock Ideas

Sell
37
Is AAPL Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 31x

Sell
37
Is MSFT Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 30x

Sell
31
Is NVDA Stock a Buy?

Market Cap: $2.3T
P/E Ratio: 32x

Alerts

Sell
45
RGC alert for Apr 5

Regencell Bioscience Holdings [RGC] is up 32.59% over the past day.

Sell
25
GDXU alert for Apr 5

MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 27.33% over the past day.

Buy
76
SOXS alert for Apr 5

Direxion Daily Semiconductor Bear 3X Shares [SOXS] is up 23.96% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock